|

Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma

RECRUITINGSponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Actively Recruiting
SponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Started2024-12-03
Est. completion2026-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07286929

Summary

The goal of modern neurooncological surgery is to obtain maximum tumor resection while preserving neurological function. Parietal lobe gliomas often cause attention deficits (hemineglect) that are difficult to differentiate from other deficits. This study aims to evaluate the extent and variation over time of visuo-spatial deficits in patients undergoing surgical removal of parietal lobe gliomas. This will help characterize the cognitive profile of these patients to identify personalized treatment and rehabilitation paths.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients \>18 years old
* Patients must understand the Italian Language
* Patients with suspected parietal lobe glioma

Exclusion Criteria:

* Tumor site other than parietal lobe.
* Patients who cannot undergo surgical resection (stereotactic/open biopsy).
* Patients who received a previous chemotherapy and/or radiotherapy treatment.
* Patients with a history of intracranial mass lesion or traumatic brain injury.
* Patients with a history of other CNS diseases (e.g., stroke, metastasis).
* Patients with diagnosis of neurodegenerative disease (i.e. Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis).

Conditions5

CancerGliomaParietal Lobe GliomaUnilateral Spatial Neglect (USN)Visuspatial Deficit

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.